{"id":29085,"date":"2024-12-16T16:05:59","date_gmt":"2024-12-16T15:05:59","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=29085"},"modified":"2024-12-16T16:16:48","modified_gmt":"2024-12-16T15:16:48","slug":"pharming-announces-a-recommended-cash-offer-to-the-shareholders-of-abliva","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/en\/assignment\/pharming-announces-a-recommended-cash-offer-to-the-shareholders-of-abliva\/","title":{"rendered":"Pharming announces a recommended cash offer to the shareholders of Abliva"},"content":{"rendered":"<p class=\"preamble\">Pharming Group N.V., through the wholly-owned subsidiary Pharming Technologies B.V., announces a recommended cash offer to the shareholders of Abliva AB to tender all shares in Abliva to Pharming at a price of SEK 0.45 in cash per share. The offer values all outstanding shares in Abliva at approximately SEK 725 million.<\/p>\n<p>Pharming is a global biopharmaceutical company commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. Pharming\u2019s shares are admitted to trading on Euronext Amsterdam and its American Depositary Shares (ADSs) are admitted to trading on Nasdaq Global Market.<\/p>\n<p>Abliva discovers and develops medicines for the treatment of mitochondrial disease. Abliva is based in Lund, and its shares are admitted to trading on Nasdaq Stockholm, Small Cap.<\/p>\n<p>Pharming is advised by Mannheimer Swartling on the offer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharming Group N.V., through the wholly-owned subsidiary Pharming Technologies B.V., announces a recommended cash offer to the shareholders of Abliva AB to tender all shares\u2026<\/p>\n","protected":false},"author":18,"featured_media":29254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4313],"tags":[],"class_list":["post-29085","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-assignment","business-group-public-ma-and-equity-capital-markets"],"acf":[],"lang":"en","translations":{"en":29085,"sv":29083},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/29085"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=29085"}],"version-history":[{"count":2,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/29085\/revisions"}],"predecessor-version":[{"id":29087,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/29085\/revisions\/29087"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/29254"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=29085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=29085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=29085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}